Children at Massachusetts Boys & Girls Clubs that ran a six-week programme called H2GO! ended the year with a lower BMI z score than children at clubs that did not, according to a cluster randomised trial published in JAMA Network Open on 1 October 2026. The difference was small and only just statistically significant, and … Read more
UBT251, an experimental once-weekly injection that acts on three hormone receptors, lowered body weight by between 13.6% and 19.7% over 24 weeks, against 2.0% on placebo, in a phase 2 trial of 205 adults in China published in Cell Metabolism on 7 October. It uses the same three-receptor approach as Lilly’s retatrutide. For patients, nothing … Read more
Australian researchers set out to pool the randomised trials of berberine in polyendocrine metabolic ovarian syndrome, or PMOS, the condition previously called polycystic ovary syndrome. Earlier reviews had presented the supplement as a match for metformin. Every eligible trial, four of them covering 452 women, was rated at high risk of compromised integrity, so none … Read more
A chemically synthesised version of semaglutide, developed by the Chinese drugmaker CSPC under the code HD1916, produced weight loss equivalent to Wegovy in a 44-week randomised trial of 462 Chinese adults with obesity, published on 7 October in Diabetes, Obesity and Metabolism. For readers in the US nothing changes yet: HD1916 is not approved here, … Read more
Most adults who stayed on tirzepatide for three years in the SURMOUNT-1 trial put back only a small part of what they had lost after reaching their lowest weight, according to a post hoc analysis published in Obesity Pillars. Of 690 participants with prediabetes who took at least three-quarters of their doses and lost at … Read more
Orforglipron, Eli Lilly’s once-daily GLP-1 pill, did not raise the risk of heart attack, stroke or cardiovascular death compared with insulin glargine in 2,749 adults with type 2 diabetes and established heart or kidney disease, according to the ACHIEVE-4 trial published in The Lancet on 30 September. It is the first cardiovascular-outcomes trial of a … Read more
Survodutide, an experimental once-weekly injection from Boehringer Ingelheim that acts on both the GLP-1 and glucagon receptors, reduced body weight by 8.2% to 9.8% over 76 weeks in adults with obesity and type 2 diabetes, against 3.9% on placebo, in a phase 3 trial published in the New England Journal of Medicine on 1 October. … Read more
A review of 34 randomised trials in PLoS Medicine has tested the standard first-line advice for polyendocrine metabolic ovarian syndrome (PMOS) — the condition long called polycystic ovary syndrome, or PCOS, recently renamed by an international consensus. Structured diet, exercise and behavioural programmes improved fasting insulin, and made regular menstrual cycles more likely, compared with … Read more